Biopharmaceutical alliances and competition: A real options games approach

International Journal of Innovation Management

Volumn 17, Issue 6, 2013, Pages

  Nigro, Giovanna Lo ^a   Morreale, Azzurra ^a   Robba, Serena ^a   Roma, Paolo ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Biopharmaceutical alliances; competition; real options games

Indexed keywords

EID: 84890086967     PISSN: 13639196     EISSN: None     Source Type: Journal    
DOI: 10.1142/S1363919613400239     Document Type: Article

References (29)

1. Black, F and M Scholes (1973). The pricing of options and corporate liabilities. Journal of Political Economy, 81(3), 637-654.
2. Carroll, JD (2012). Top 20 biotech licensing deals in H1. Available at http://www.fiercebiotech.com/special-reports/top-20-biotech-licensing-deals-h1- 2012/top-20-biotech-licensing-deals-h1-2012.
3. Chance, D (1998). Essays in Derivatives. New Hope, PA: Frank J. Fabozzi Associates.
4. Chevalier-Roignant, B, CM Flath, A Huchzermeier and L Trigeorgis (2011). Strategic investment under uncertainty: A synthesis. European Journal Operational Research, 215(3), 639-650.
5. Dahlander, L and DM Gann (2010). How open is innovation Research Policy, 39(6), 699-709.
6. Deloitte (2005). Critical factors for alliance formation: Insights from the Deloitte Research Biotech Alliance Survey, Deloitte Development LLC.
7. Dhankhar, A, M Evers and M Møller (2012). Escaping the sword of Damocles: Toward a new future for pharmaceutical R&D. McKinsey Perspectives on Drug and Device R&D.
8. Dixit, A and R Pindyck (1994). Investment Under Uncertainty. Princeton, NJ: Princeton University Press.
9. Du, J, B Leten and W Vanhaverbeke (2013). Timing and heterogeneity of collaboration outcomes. Strategic Management Society Special Conference, Lake Geneva, March 20-23.
10. FierceBiotech (2007). The biotech market share report. Available at http://www.fiercebiotech. com/special-reports/biotech-marketshare-report.
11. Gassmann, O and G Reepmeyer (2005). Organizing pharmaceutical innovation: From science-based knowledge creators to drug-oriented knowledge brokers. Creativity and Innovation Management, 14(3), 233-245. (Pubitemid 41288124)
12. Hartmann, M and A Hassan (2006). Application of real option analysis for pharmaceutical R&D project valuation - Empirical results from a survey. Research Policy, 35(3), 343-354.
13. Kalamas, J, GS Pinkus and K Sachs (2002). The new math for drug licensing. McKinsey Quarterly, 9-12.
14. Kleyn, D and R Kitney (2007). Partnership and innovation in the life sciences. International Journal of Innovation Management, 11(2), 323-347.
15. Lo Nigro, G, A Morreale and G Enea (2013). Open innovation: A real option to restore value to the biopharmaceutical R&D. International Journal of Production Economics. Available at http://dx.doi.org/10.1016/j.ijpe.2013.02.004.
16. Martzoukos, SH and E Zacharias (2013). Real option games with R&D and learning spillovers. Omega, 41(2), 236-249.
17. Mason, R and H Weeds (2005). Can greater uncertainty hasten investment Working Paper, Southampton University and CEPR.
18. Mazzola, E, M Bruccoleri and G Perrone (2012). The effect of inbound, outbound and coupled innovation on performance. International Journal of Innovation Management, 16(6), 1-27.
19. McBride, R (2013). Celgene taps biotech Forma for drug in hot field of protein homeostasis. April 29. Available at http://www.fiercebiotech.com/story/ celgene-taps-biotech-forma-drugs-hot-field-protein-homeostasis/2013-04-29.
20. Napodano, J (2009). Biotech companies face the key question - Deal or no deal June 4. Available at http://www.genengnews.com/insight-and- intelligenceand153/biotech-companies-face-the-key-question-deal-or-no-deal/ 55682893/.
21. Nicholson, S, PM Danzon and J Mccolough (2005). Biotech-pharmaceutical alliances as a signal of asset and firm quality. Journal of Business, 78(4), 1433-1464. (Pubitemid 41560712)
22. Niosi, J (2003). Alliances are not enough explaining rapid growth in biotechnology firms. Research Policy, 32(5), 737-750.
23. Phrma (2013). Biopharmaceutical Research Industry Profile. Washington, DC: Phrma.
24. Rogers, MJ, CD Maranas and M Ding (2005). Valuation and design of pharmaceutical R&D licensing deals. American Institute of Chemical Engineers Journal, 51(1), 198-209. (Pubitemid 40116351)
25. Rogers, M, J Gupta and CD Maranas (2002). Real options based analysis of optimal pharmaceutical research and development portfolios. Industrial and Engineering Chemistry Research, 41(25), 6607-6620. (Pubitemid 35429854)
26. Schatzman, R (2013). Industry voices: Place your bets - A horse race emerges in the migraine space. September 9. Available at http://www. fiercebiotech.com/story/industry-voices-place-your-bets-horse-race-emerges- migraine-space/2013-09-09.
27. Smit, HTJ and L Trigeorgis (2007). Strategic options and games in analyzing dynamic technology investments. Long Range Planning, 40(1), 84-114. (Pubitemid 46672863)
28. Toonkel, J (2013). Biotech firms evolve from targets to acquirers. May 8. Available at www.reuters.com.
29. Trigeorgis, L (1996). Real Options. Cambridge, MA: MIT Press.